



(51) International Patent Classification:

A61P 31/14 (2006.01) A61P 9/12 (2006.01)
C12N 9/48 (2006.01) A61P 11/00 (2006.01)
A61K 38/48 (2006.01) A61P 13/12 (2006.01)

(21) International Application Number:

PCT/EP2021/063692

(22) International Filing Date:

21 May 2021 (21.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20176139.2	22 May 2020 (22.05.2020)	EP
20204774.2	29 October 2020 (29.10.2020)	EP
20210297.6	27 November 2020 (27.11.2020)	EP
21164684.9	24 March 2021 (24.03.2021)	EP
21170519.9	26 April 2021 (26.04.2021)	EP

(71) Applicant: **FORMYCON AG** [DE/DE]; Fraunhoferstraße 15, 82152 Martinsried/Planegg (DE).

(72) Inventors: **REITER, Alwin**; Ringseisstraße 11 A, 80337 München (DE). **BROCKMEYER, Carsten**; Sena-

tor-Ernst-Str. 2, 85417 Marzling (DE). **WOLSCHIN, Florian**; Johannisplatz 13, 81667 München (DE).


(74) Agent: **MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH**; LASAR, Andrea, Elisenhof, Elisenstraße 3, 80335 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ACE2-FC FUSION PROTEINS AND USES THEREOF

Figure 9



(57) Abstract: The present invention relates to fusion proteins of ACE2 with IgG Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

13 January 2022 (13.01.2022)